Can Changes in Dialysate Sodium Concentration Improve Blood Pressure and Endothelial Function in Chronic HD Patients?
NCT07459348 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25
Last updated 2026-03-13
Summary
People with end stage kidney disease cannot regulate salt and water normally, which often leads to high blood pressure, fluid overload, and a higher risk of heart disease.
Hemodialysis is a life sustaining treatment that removes waste products, excess fluid, and electrolytes from the blood. However, the treatment itself can influence blood pressure and how the blood vessels function. Many patients experience symptoms such as thirst, headaches, fatigue, and swelling, which affect both daily well being and long term health. One possible way to reduce these problems may be as simple as adjusting the amount of sodium in the dialysis fluid.
During dialysis, substances move between the patient's blood and the dialysate, the special fluid used in the machine. Sodium is one of the most important components because it helps regulate fluid balance and blood pressure. A higher sodium concentration in the dialysate can make patients feel more thirsty, cause them to drink more, and lead to fluid retention and higher blood pressure. On the other hand, lowering sodium too much can cause dizziness, low blood pressure, cramps, and discomfort during treatment. Because of this, there is ongoing debate about what the "right" sodium level should be.
Too much sodium over time may also harm the blood vessels. The inner lining of the vessels, called the endothelium, is protected by a thin layer known as the glycocalyx. This layer helps prevent sodium from entering the vessel wall and supports the production of nitric oxide, a molecule that relaxes blood vessels and reduces inflammation. High salt exposure can damage the glycocalyx and reduce nitric oxide production, making the vessels stiffer and raising blood pressure. In dialysis patients, low nitric oxide levels are linked to worse outcomes and episodes of rising blood pressure during treatment. Some small studies suggest that lowering dialysate sodium can improve blood pressure and endothelial function, but larger studies have not shown clear effects on survival. This indicates that we still do not fully understand which patients benefit most or how sodium changes affect both physical and subjective symptoms.
This study aims to fill these knowledge gaps by examining how a lower sodium concentration in the dialysate affects blood pressure, blood vessel function, fluid overload, inflammation, and patient reported symptoms. The goal is to provide new insights that could help tailor dialysis treatment to individual patients in a simple and cost effective way.
The study will compare two sodium concentrations: a lower level (133 mmol/L) and the standard level used in many clinics (139 mmol/L). Twenty five patients receiving chronic in center hemodialysis will participate. Each patient will undergo both treatments for three weeks each, in random order, with a two week washout period in between. This crossover design allows each patient to serve as their own control, making it easier to detect meaningful differences.
The main outcome is the difference in 24 hour systolic blood pressure between the two sodium levels. Secondary outcomes include changes in nitric oxide levels in the blood, measures of fluid overload using two different techniques, markers of inflammation, arterial stiffness, and patient reported symptoms such as thirst, fatigue, and overall well being. The study will also compare two methods for assessing fluid overload: bioimpedance spectroscopy and a newer carbon monoxide rebreathing technique.
Blood pressure and arterial stiffness will be measured over 44 hours using a portable device. Blood samples will be collected to analyze nitric oxide, inflammatory markers, and sodium handling in red blood cells. Fluid status will be measured using both bioimpedance and the CO rebreathing method. Patients will complete a weekly questionnaire developed together with dialysis patients to capture their experiences and symptoms.
Conditions
- Dialysis Dependent Chronic Kidney Disease
- Dialysis Patients
- Sodium Excess
- High Blood Pressure
Interventions
- DEVICE
-
Low-Sodium Dialysate (133 mmol/L)
Hemodialysis performed with dialysate sodium concentration of 133 mmol/L.
- DEVICE
-
Standard-Sodium Dialysate (139 mmol/L)
Hemodialysis performed with dialysate sodium concentration of 139 mmol/L.
Sponsors & Collaborators
-
Gødstrup Hospital
lead OTHER
Principal Investigators
-
Jesper N Bech, Consultant, Professor · University Clinic in Nephrology and Hypertension
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-05-01
- Primary Completion
- 2028-12-31
- Completion
- 2029-12-31
Countries
- Denmark
Study Locations
More Related Trials
-
Dialysate Sodium Individualization in Hemodialysis
NCT00259714 ·Status: TERMINATED ·Phase: PHASE1
-
Haemodialysis Salt Reduction Study
NCT00141609 ·Status: COMPLETED ·Phase: NA
-
Dietary Sodium Restriction in Hemodialysis Patients
NCT01896882 ·Status: UNKNOWN ·Phase: NA
-
Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients
NCT02145260 ·Status: COMPLETED ·Phase: NA
-
Timing of Antihypertensive Medications on Key Outcomes in Hemodialysis
NCT03327909 ·Status: COMPLETED ·Phase: NA
-
Sodium-restricted Diets and Symptoms in End Stage Renal Disease: An RCT
NCT02778516 ·Status: COMPLETED ·Phase: NA
-
Concentrated Saline Infusions and Increased Dietary Sodium With Diuretics for Heart Failure With Kidney Dysfunction
NCT00575484 ·Status: TERMINATED ·Phase: PHASE2
-
Steroids on Intra-dialytic Hypotension
NCT03465007 ·Status: COMPLETED ·Phase: NA
-
Sodium-Endothelial Function-CKD Study
NCT00141622 ·Status: COMPLETED ·Phase: NA
-
Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease
NCT01918488 ·Status: UNKNOWN ·Phase: NA
-
Lowering Salt Intake in Chronic Kidney Disease: A Pilot Randomized Crossover Trial
NCT00974636 ·Status: COMPLETED ·Phase: NA
-
Association of Diuretics With Change in Extracellular Volume, Natriuretic Peptides, Symptoms, and Cardiovascular Outcomes in CKD
NCT04192110 ·Status: WITHDRAWN ·Phase: PHASE4
-
Mechanisms and Treatment of Intradialytic Hypertension
NCT00827775 ·Status: COMPLETED ·Phase: PHASE4
-
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
NCT04040959 ·Status: RECRUITING ·Phase: PHASE2
-
Improving Outcomes in Patients With Kidney Disease Due to Diabetes
NCT00381134 ·Status: COMPLETED ·Phase: PHASE2
-
Tissue Sodium in Pre-hypertensive Patients
NCT02236520 ·Status: COMPLETED ·Phase: PHASE2
-
The Role of Skin Sodium Accumulation in Chronic Kidney Disease
NCT07020104 ·Status: RECRUITING ·Phase: NA
-
Spironolactone Safety in Dialysis Patients
NCT00328809 ·Status: WITHDRAWN ·Phase: PHASE4
-
Effects of Intensive Low-Salt Diet Education by Mobile Application on Albuminuria
NCT03396328 ·Status: COMPLETED ·Phase: NA
-
Hypertension in Hemodialysis Patients (Aim 3)
NCT00582114 ·Status: TERMINATED ·Phase: PHASE3
-
Treating Metabolic Acidosis in Chronic Kidney Disease to Prevent Adverse Kidney and Cardiovascular Outcomes
NCT06545461 ·Status: COMPLETED ·Phase: NA
-
Aldosterone Blockade in Chronic Kidney Disease: Influence on Arterial Stiffness and Kidney Function
NCT01100203 ·Status: TERMINATED ·Phase: PHASE3
-
Is Hemodialysis Associated With Cardiac Markers Change?
NCT04929366 ·Status: COMPLETED ·Phase: NA
-
Cardiovascular Protective Effect of Spironolactone in Hemodialysis
NCT00277693 ·Status: UNKNOWN ·Phase: PHASE4
-
Hemodialysis.-Induced Hypotension Therapy for End Stage Kidney Disease
NCT05297786 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2